Stimwave Technologies recently announced that it named Aure Bruneau as CEO, effective immediately. Bruneau succeeds Paul LaViolette, who was appointed interim CEO in late 2019. “Are is a perfect match for the next fast-growth chapter at Stimwave,” LaViolette said in a news release. “He is a truly customer-centric leader and will continue our rapid expansion […]
Stimwave caves in patent spat with Nevro
Stimwave today announced it will cease all sales of its high-frequency spinal cord stimulation systems in exchange for dismissal of a patent infringement lawsuit brought by rival Nevro (NYSE:NVRO). No damages were awarded to Nevro under the settlement. Redwood City, Calif.-based Nevro brought the suit in February 2019, alleging that Stimwave infringed on patents related to […]
Stimwave Technologies stops commercialization of products in Australia
Stimwave Technologies announced today that it is stopping the commercialization of its product lines in Australia until its entire product family can be legally marketed in the country. The neuromodulation therapy alternative developer’s products include the Freedom SCS system and the StimQ PNS system, which are designed to reduce the risks associated with implantable pulse […]
Stimwave appeals injunction in Nevro patent war
Stimwave yesterday appealed a preliminary injunction barring it from using higher-frequency neurostim to treat chronic pain in a patent spat with rival Nevro (NYSE:NVRO). Redwood City, Calif.-based Nevro brought the suit in February, alleging that Stimwave infringed on patents related to Nevro’s Senza system and HF10 therapy. The lawsuit, filed in the U.S. District Court for Delaware, […]
Nevro wins partial injunction in patent spat with Stimwave
A federal judge in Delaware yesterday granted a preliminary injunction to Nevro Corp. (NYSE:NVRO) barring neuromodulation rival Stimwave from using higher-frequency neurostim to treat chronic pain. Redwood City, Calif.-based Nevro brought the suit in February, alleging that Stimwave infringed on patents related to Nevro’s Senza system and HF10 therapy. The lawsuit, which was filed in the U.S. […]
Ablative Solutions taps medtech vet Rumrill for CEO | Personnel Moves, July 16, 2019
Ablative Solutions tapped 30-year industry veteran Kate Rumrill, the former chief executive at NeoSync, to be its new president & CEO. Rumrill, whose resume includes stints at Covidien, Aspect Medical Systems and Eli Lilly, is slated to keep her seat on NeoSync’s board, San Jose, Calif.-based Ablative Solutions said. The company makes the Peregine renal […]
Stimwave calls Nevro patent suit ‘baseless, unfounded’
Stimwave today responded to a patent infringement suit filed by Nevro (NYSE:NVRO) stating that the claims made against the company are “completely baseless, unfounded and invalid.” In its suit, which was filed in the U.S. District Court for the District of Delaware last week, Nevro claims that Pompano Beach, Fla.-based StimWave infringed on patents related to […]
Stimwave touts 6 month MIS SCS trial results
Stimwave today touted six-month data from a trial of its minimally invasive spinal cord stimulator system. The company’s pivotal Surf trial compared a variety of waveform options without the need for separate trial devices. Stimwave reported that in the high and low frequency groups, back and leg pain responders were more than 92% and 86%, […]
StimWave wins FDA nod for Apple iOS-based WaveCrest mobile SCS patient controller
Stimwave said yesterday it won FDA 510(k) clearance for an Apple (NSDQ:AAPL) iOS device version of its WaveCrest Mobile platform patient controller application for pain management. The newly cleared system from the Pompano Beach, Fla.-based company allows patients with iPhone and Apple Watch devices to control WaveMaster multi-waveform automated programming for the company’s Wireless Freedom spinal […]
Dr. Gawande tapped to lead Amazon-JPM-Berkshire health play | Personnel Moves – June 21, 2018
The joint healthcare venture between Amazon (NSDQ:AMZN), Berkshire Hathaway and J.P. Morgan Chase said this week it named Brigham and Women’s Hospital surgeon, New Yorker magazine staff writer and bestselling author Dr. Atul Gawande as its CEO, effective July 9. The joint venture said that the newly formed company will be headquartered in Boston, and will operate […]
Stimwave raises $50m for consumer launch of chronic pain neuromod device
Stimwave said this week that it raised more than $50 million from a consortium of unnamed investors for the consumer launch of its Freedom neuromodulation device for treating chronic pain. Pompano Beach, Fla.-based Stimwave said the Freedom stimulator is the sole FDA-approved wireless, micro-sized device cleared for treating neuropathic pain. The device uses a tiny injectable microchip […]
